{
    "Trade/Device Name(s)": [
        "ARCHITECT i Vancomycin",
        "ARCHITECT / Vancomycin"
    ],
    "Submitter Information": "Biokit S.A.",
    "510(k) Number": "K123947",
    "Predicate Device Reference 510(k) Number(s)": [
        "K072036"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LEH"
    ],
    "Summary Letter Date": "August 29, 2013",
    "Summary Letter Received Date": "July 25, 2013",
    "Submission Date": "July 23, 2013",
    "Regulation Number(s)": [
        "21 CFR 862.3950"
    ],
    "Regulation Name(s)": [
        "Vancomycin test system"
    ],
    "Analyte Class(es)": [
        "toxicology",
        "tdm"
    ],
    "Analyte(s)": [
        "Vancomycin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube",
        "Dipotassium EDTA tube",
        "Sodium citrate tube",
        "Sodium heparin tube",
        "Sodium fluoride/potassium oxalate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT i System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent microparticle immunoassay (CMIA)"
    ],
    "Methodologies": [
        "Immunoassay",
        "Chemiluminescent detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ARCHITECT i Vancomycin chemiluminescent immunoassay for quantitative measurement of vancomycin in serum and plasma",
    "Indications for Use Summary": "Quantitative in vitro measurement of vancomycin in human serum or plasma to aid in diagnosis and treatment of vancomycin overdose and monitoring of therapeutic levels",
    "fda_folder": "Toxicology"
}